"The Ceftiofur Long Acting to Reduce Antibiotics (CLARA) is a new technology project for large animal pharmaceutical products with one shot, long acting treatment, based on a widely recognized molecule. It will result in a long acting antibiotic injection process (one shot / 7 to 8 days) of Ceftiofur to treat farm animals against important infectious diseases on respiratory and digestive systems, with a very short delay. This new technology for delivering antibiotics will help to: reduce the quantity of antibiotic delivered, reduce the number of injection or delivery, improve tolerance for animals and improve food chain safety. So-called Hydrogels, obtained through hydratation of high technologies polymers (PLA and PEG), will be the base of the technology for this innovation. Small and Medium Sized Enterprises participating to the project will have a total control on the Project Results property and on the dissemination process. As the project is completely SME and industry driven, there is also a unique commitment to disseminate the veterinary products resulting of the project in every European country and, to diffuse them on the worldwide market with great opportunities on emerging and fast growing markets (Asia and Pacific). The project starts from pure R&D actions to clinical fields trials to control efficacy of the candidate product on the targeted species. After the project end, the Coordinator, on behalf of the Consortium and in the interest of participating SMEs, will reach a pan-European registration through central or decentralized registration in all the Member States to deliver quickly the new product to the animal health market through. The Consortium includes Animal Health Pharmaceutical SMEs individually recognized as references in their respective country. The 24 months project is based on a recognized antibiotic molecule (Ceftiofur) and an awarded delivery technology (Medincell) based on 20 years of European research at French CNRS."